Alto Neuroscience opened lower at $30.44, compared with its previous close of $31.15. In the last trading session, the stock traded between $30.35 and $33.50. It showed a downward intraday trend.
An investment of $100 made 3 years ago in Alto Neuroscience is now worth
$ 147.81
Giving a profit of
$ 47.81 (47.81%)
Note: Past profits do not guarantee future returns.
Rating from 6 Analysts
Today's Change
$-0.55 (-1.78%)
Day High
$33.50
Day Low
$30.35
Day Open
$30.44
Prev Close
$31.15
Volume
10,07,731
1W Return
31.48%
1M Return
26.50%
3M Return
6.27%
6M Return
24.73%
1Y Return
128.34%
Market Cap ($ Mn)
1,227
PE Ratio
-
PB Ratio
5.62
PEG Ratio
-
ROE
-46.73%
ROCE
-42.47%
EPS (TTM)
-
1 Week
31.48%
1 Month
26.50%
3 Months
6.27%
6 Months
24.73%
9 Months
83.11%
Alto Neuroscience promotes Nick Smith to president and CFO
Nick Smith promoted to president and CFO at Alto Neuroscience. Effective date for the new role is August 26, 2026. Role expands to include oversight of corporate strategy and business development. Smith joined the company in 2021 and became CFO in 2022.
2mo agoHC Wainwright raises Alto Neuroscience price target to $55
HC Wainwright & Co. analyst Patrick R. Trucchio maintains a Buy rating on Alto Neuroscience (NYSE: ANRO). The price target was increased from $50 to $55, indicating a positive revision in the firm's valuation model for the biotechnology company.
2mo agoAlto Neuroscience Q2 EPS beats estimates; completes $100M financing
Alto Neuroscience reported Q2 2026 EPS of $(0.65), beating estimates of $(0.73). Net loss widened to $27.6 million due to higher R&D spend. A $100 million July financing brings pro forma cash to $338 million. Pipeline updates include a new Phase 3 monotherapy trial for ALTO-207 and positive independent study results published in Nature Medicine.
3mo agoAlto Neuroscience prices $100M offering to fund trials
Alto Neuroscience, Inc. announced the pricing of a $100 million underwritten registered direct offering of 3,776,436 shares at $26.48 per share, expected to close on July 14, 2026. Proceeds will support the clinical development of ALTO-207, with the company reporting an estimated cash position of $244.2 million as of June 30, 2026. The offering is led by EcoR1 Capital and managed by BofA Securities, Stifel, William Blair, and Baird.
4mo agoAlto Neuroscience highlights pramipexole study results
Alto Neuroscience highlighted results from the PRIME-PRAXOL trial published in Nature Medicine, demonstrating that pramipexole significantly reduced anhedonia compared to placebo. The study showed a mean difference of −4.04 on the SHAPS scale (p=0.006) and sustained improvements through six months. These findings support the dopaminergic mechanism of ALTO-207, a fixed-dose combination therapy currently in a Phase 2b trial for treatment-resistant depression with data expected in 2H 2027.
5mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 3 years ago in Alto Neuroscience is now worth
$ 147.81
Giving a profit of
$ 47.81 (47.81%)
Note: Past profits do not guarantee future returns.
